Physician profile
Dale Patrick Yu
NPI 1174506646
$7,705.61
in general payments reported to CMS, 2019-2025
36 companies · $1,068 in 2025
The $1,068 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,191 · 2020: $1,010 · 2021: $1,341 · 2022: $1,000 · 2023: $1,045 · 2024: $1,051 · 2025: $1,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,163.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,863.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,118.41 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $517.90 | 2019-2025 | |
| Novo Nordisk INC | $485.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $476.47 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $445.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $387.80 | 2019-2023 | Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.55 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Amarin Pharma, INC. | $270.91 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $204.55 | 2019-2025 | Zoryve |
| Amgen INC. | $198.60 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $196.80 | 2019-2021 | |
| Axsome Therapeutics, INC. | $150.81 | 2022-2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $138.77 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $134.07 | 2019-2022 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dale Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.